Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating [Yahoo! Finance]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Yahoo! Finance
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS is among the 10 Fastest Growing NASDAQ Stocks to Buy Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating On February 25, 2026, Oppenheimer analyst Andreas Argyrides raised the firm's price target on Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) to $105 from $95 and maintained an Outperform rating following quarterly results. Management also provided first-time FY26 net product sales guidance of $670M–$700M for XDEMVY, representing a year-over-year increase of $230M driven by new patient demand, broad payer coverage, and effective direct-to-consumer efforts. The analyst said the outlook puts XDEMVY on track to achieve more than $2B in peak U.S. sales. Also on February 25, 2026, Guggenheim raised its price target on Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) to $90 from $87 and reiterated a Buy rating after the company reported what the firm described as “strong” 2025 results
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Pharmaceuticals (TARS) was upgraded by Lifesci Capital to "strong-buy".MarketBeat
- Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Mixed Share Performance [Yahoo! Finance]Yahoo! Finance
- Tarsus Pharmaceuticals (TARS) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TARS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from MarketBeat
- Tarsus Pharmaceuticals (TARS) was downgraded by Zacks Research from "strong-buy" to "hold".MarketBeat
TARS
Earnings
- 2/23/26 - Miss
TARS
Sec Filings
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- TARS's page on the SEC website